NORMAL SITUATION

Charlotte De Sutter

Export PDF

Company — Normal situation.

Financial year 2025 · Closed on 17/02/2025

Net result-80,6 €-100,1 %over 1 year
Equity279,8 k €-0,0 %over 1 year

Identity

Source · BCE/KBO

Charlotte De Sutter is a company registered in Belgium.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0831.893.774
Legal form
Private company with limited liability
Contributed capital
90 000,00 €
Latest accounts
17/02/2025
Signals
Solid equityGood liquidity

Financials

Source · NBB, 15 filings

Trend over 15 financial years

20252024202320222021
Income statement
Gross margin–-3,8 k €-4,5 k €-2,9 k €-516,6 €
EBITDA–-3,8 k €-4,6 k €-2,9 k €-726,8 €
Operating result–-3,8 k €-4,6 k €-2,9 k €-726,8 €
Net result-80,6 €120,8 k €-12,2 k €-9,7 k €-7,2 k €
Balance sheet
Equity279,8 k €279,9 k €159,1 k €171,3 k €181 k €
Total assets279,9 k €279,9 k €947,3 k €947,7 k €951,4 k €
Cash279,9 k €279,9 k €57,7 €23,6 €4,2 k €
Debts46,1 €46,1 €780,8 k €769,8 k €766,1 k €

Board of directors

Source · NBB, accounts to 17/02/2025

1 active · 7 ended

Active mandates

PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Active

Ended mandates

PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
Pierre De Witte

Manager · since 01 novembre 2013 · until 30 septembre 2017

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year17/02/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year2 months12 months12 months12 months12 months12 months
Filing date01/09/202515/07/202519/07/202403/07/202329/08/202230/08/2021
General meeting17/02/202520/06/202521/06/202416/06/202317/06/202218/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 15 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model17/02/202517/02/202501/09/2025DutchPDF
Abridged model31/12/202420/06/202515/07/2025DutchPDF
Abridged model31/12/202321/06/202419/07/2024DutchPDF
Abridged model31/12/202216/06/202303/07/2023DutchPDF
Abridged model31/12/202117/06/202229/08/2022DutchPDF
Abridged model31/12/202018/06/202130/08/2021DutchPDF
Abridged model31/12/201919/06/202025/09/2020DutchPDF
Abridged model31/12/201821/06/201926/08/2019DutchPDF
Abridged model31/12/201715/06/201824/08/2018DutchPDF
Abridged model31/12/201616/06/201729/08/2017DutchPDF
Abridged model31/12/201517/06/201623/08/2016DutchPDF
Abridged model31/12/201419/06/201518/08/2015DutchPDF
Abridged model31/12/201320/06/201429/07/2014DutchPDF
Abridged model31/12/201221/06/201308/08/2013DutchPDF
Abridged model31/12/201115/06/201210/07/2012DutchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 17/02/2025

1 active · 7 ended

Active mandates

PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Active

Ended mandates

PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
Pierre De Witte

Manager · since 01 novembre 2013 · until 30 septembre 2017

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Dissolution04/03/2025
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ...
    PDF
  • Mandates24/10/2017
    MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates17/12/2013
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-80,6 €↓
  2. 2024
    Annual accounts 2024120,8 k €↑
  3. 2023
    Annual accounts 2023-12,2 k €↓
  4. 2022
    Annual accounts 2022-9,7 k €↓
  5. 2021
    Annual accounts 2021-7,2 k €↓
  6. 2020
    Annual accounts 202013,1 k €↑
  7. 2019
    Annual accounts 20194,1 k €↓
  8. 2018
    Annual accounts 201827 k €↑
  9. 2017
    Annual accounts 2017-355,5 €↓
  10. 2016
    Annual accounts 20164,3 k €↑
  11. 2015
    Annual accounts 20154 k €↓
  12. 2014
    Annual accounts 201411,1 k €↓
  13. 2013
    Annual accounts 201314,6 k €↑
  14. 2012
    Annual accounts 201211,1 k €↑
  15. 2011
    Annual accounts 20119,2 k €